PANGAEA ONCOLOGY

Trading sesion


25/04/2024

-

Last price


52.14 mill. €

Capitalisation

-

Dif.(%)


-7.07

% Year 2024

Last Trade

Date

25/04/2024

Hour

Last

-

Ref.

1.7100

Dif.(%)

-

Volume (Shares)

-

Turnover (€x1000)

-

X
25/04/2024 13:05:33
BidAsk
OrdersVolumePricePriceVolumeOrders
12,9241.71001.79002,7941

Security

Security name

PANGAEA ONCOLOGY

Ticker

PANG

ISIN

ES0105221008

NIF

A-64353584

Shares Admitted

30.489.770

Nominal

0,02 Euros

Capital Admitted

609.795,40 Euros

Trading

Fixing

Liquidity Provider

GVC GAESCO VALORES, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

ERNST & YOUNG S.L.

Address

CALLE COSO 42, 50004 ZARAGOZA

Contact

info@panoncology.com

Historical Summary

 20202021202220232024 until 24/04

Capital Admitted (thousands of euros)

338451610610610

Shares (x 1,000)

16,88722,53330,49030,49030,490

Period Close Price (euros)

1.60001.57001.64001.84001.7100

Period Last Price (euros)

1.60001.57001.64001.84001.7100

Period High Price (euros)

1.70002.70001.81002.42001.9100

Period Low Price (euros)

0.97001.40001.31001.62001.7100

Capitalisation (thousands of euros)

27,01835,37750,00356,10152,138

Volume (thousands of shares)

2,8047,5313,1373,2101,699

Turnover (thousands of euros)

3,82211,1064,3414,8103,176

Company Profile

Pangaea Oncology is a medical services company focused on precision oncology, whose mission is to improve the survival and quality of life of patients and to promote the development of breakthrough technologies with high added value. In this sense, one of the entity's main objectives is to provide services for the optimization of therapies under development for its clients. The company has two distinct business areas: i) its healthcare division, based on the concept of personalized medicine (through its different affiliates IOR -Instituto Oncológico Dr. Rosell-, IBCC -International Breast Cancer Center-, IOB -International Oncology Bureau-, and QTI -Quenet Torrent Institute-), active in some of most important hospitals of the Quirónsalud Group in Spain; and (ii) its services division to the pharmaceutical industry, through a state-of-the-art laboratory with proprietary technology and a research team of the highest excellence, where the Company works for the world's leading pharmaceutical companies. Pangaea has a high research and development component, focused on proprietary diagnostitechnologies (with special emphasis on Liquid Biopsy and NGS -Next Generation Sequencing-), and a platform of more than 400 in vitro models that allow optimization of new drugs in development, generating more than 75 scientific publications in peer reviewed journals, per year. In the future, the company's R&D strategy will be complemented with early cancer detection technologies and Big Data and Artificial Intelligence models. The relationship of these areas is the foundation of Pangea's growth strategy.

Inside Information

Other Relevant Information

Notices

Relevant Facts until 10/05/2020

Significant participations

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.